Process distance, not medical scarcity, defines sickle cell care gap

Summary

A national survey of 100 US healthcare providers measured a 91-to-3 gap between red blood cell exchange equipment availability and therapy delivery for sickle cell patients, locating the defining structural feature of the gap in process distance rather than medical scarcity.
Lead author Aaron Haubner of the University of Kentucky College of Pharmacy and Dr. Edward Donnell Ivy of the Sickle Cell Disease Association of America identified six compounding failure points — patient awareness, provider guideline familiarity, referral pathways, insurance coverage, donor blood supply, and inter-departmental coordination — each documented in the survey as a barrier.
Dr. Shannon Kelly of UCSF Benioff Children’s Hospital Oakland documented that large institutions refer out for lack of dedicated apheresis programs and that rural hospitals cannot sustain the procedural competency low patient volumes require.
Sickle cell disease distribution co-varies with the geography of absent care: more than 100,000 US patients, 90 percent non-Hispanic Black or African American, approximately 80 percent Medicaid-enrolled, concentrated in rural Southern states.

A national survey of 100 US healthcare providers published Sunday found that 91 percent of providers who manage sickle cell patients reported having the technology to perform automated red blood cell exchange, while fewer than 3 percent of patients had been recorded as receiving it. The gap is not one of equipment; it is one of delivery, shaped by where the centers sit, how the handoffs between departments run, and how the disease is distributed across a country whose map of expertise does not match the map of patient need. The barrier most often cited by providers was not the technology itself but the coordination required to bring it to a patient.

The geographic mismatch

Sickle cell disease affects more than 100,000 people in the United States and 8 million worldwide, according to the National Heart, Lung, and Blood Institute. Among US patients, 90 percent are non-Hispanic Black or African American and an estimated 3 to 9 percent are Hispanic or Latino; approximately 80 percent of US sickle cell patients are enrolled in Medicaid. Ivy described the distribution in reported remarks: “A lot of sickle cell patients live in rural areas and so only have access to rural hospitals. If you look at the distribution of sickle cell disease, it primarily affects African Americans who tend to be in states in the south that can be more rural, and so have less access to some of these equipment. And these rural hospitals may be less likely to have access to these therapies.”

The comprehensive centers that combine hematology, apheresis, transfusion medicine, nurse education, and care coordination — what Haubner called “centers of excellence” — cluster around academic medical centers in metropolitan areas. Read through Kevin Lynch’s image-of-the-city vocabulary, developed in studies of Boston, Jersey City, and Los Angeles, the centers are the nodes — strategic spots where paths converge and concentrated expertise justifies a long journey. The patient population is distributed across a wide set of districts — Southern states, rural counties, communities historically under-resourced for specialist care — with weak edges between them: state lines, insurance networks, and the rural-to-urban referral corridor. Distant landmarks for a sickle cell patient seeking automated red blood cell exchange are few; local landmarks, including community hospitals, are many, but the procedure passes through them rather than residing in them. The disease distribution is co-structured by race, income, and rurality rather than by clinical need alone. Process distance is measured along racial and economic lines as much as along miles.

Six failing handoffs

The procedure that the survey measured requires what Haubner described as “coordinated access to hematologists, transfusion and apheresis specialists, nurse educators, care coordinators, and other support services.” Each handoff in the patient journey is a potential friction zone, and the survey identifies at least six sequential decision points, each with a documented failure mode.

Patient awareness is the first. “Barriers include patients not being aware to ask about certain therapies, but it is also important for patients to have doctors that are knowledgable about how to treat sickle cell disease, about the risk factors too,” Ivy said. The therapy becomes one the patient must request rather than one the system offers by default.

Provider familiarity with treatment guidelines is the second. “There’s a gap between the number of providers who understand how to treat sickle cell disease,” Ivy said.

The referral pathway is the third. Kelly described the upstream bottleneck: “We get referrals to my hospital from other large institutions, where even they don’t have a dedicated apheresis program [involving a centrifuge machine that processes blood from the patient’s body] that provides automated red blood cell exchange. The issue is more that this therapy is not at enough institutions and hospitals.”

Reimbursement and insurance coverage is the fourth. The survey identified whether red blood cell exchange therapy was covered by patients’ health insurance as a major patient concern. With roughly 80 percent of US sickle cell patients enrolled in Medicaid, state-variable coverage shapes whether the therapy arrives in a clinic as a covered benefit or as an out-of-pocket exposure for a population already carrying socioeconomic vulnerabilities.

Donor blood supply is the fifth. Providers cited this among the most common obstacles. Sickle cell patients requiring extended antigen matching depend on a small subset of the donor pool; the supply of matched units is a constraint distinct from the equipment and coordination problems that drive the rest of the gap.

Inter-departmental coordination at the receiving institution is the sixth — and the most-cited barrier in the survey. It requires simultaneous availability of hematologists, transfusion and apheresis specialists, nurse educators, and care coordinators.

The survey’s finding that only 5 percent of providers reported encountering no barriers indicates that at least one of these handoffs is failing for nearly every patient in the sample. Read as a constructed analytical model — the survey names the barriers but does not measure their joint distribution — and treated as approximately independent, the six barrier probabilities compound to a near-zero joint probability of receiving the indicated therapy. The survey’s 3 percent figure appears to be the aggregate output of that compounding, a result no single-barrier analysis could have produced. In the operations vocabulary developed by Eliyahu Goldratt in The Goal (1984) and the surrounding Theory of Constraints literature, the binding constraint here is not the technology but the practice that keeps the technology competent. The 91 percent figure describes the equipment; the 3 percent figure describes the practice.

The character of the receiving place

In Christian Norberg-Schulz’s phenomenological sense, developed in Genius Loci: Towards a Phenomenology of Architecture (1979/1980), the comprehensive center’s genius loci is a place of gathered expertise and concentrated practice: the synthesis of a specialized transfusion service, an apheresis team, donor coordination, and longitudinal case management — a “spirit of place” that does not exist as a portable set of equipment. The rural hospital’s genius loci is a place of generalized care, where sickle cell is one of many conditions competing for attention. The two places are different in character, not failures of each other. The patient who needs automated red blood cell exchange must travel between them. Haubner observed: “In many communities — outside of dedicated centers of excellence — these resources simply aren’t available.”

Two proposed framings

Haubner advanced what can be called an infrastructure framing: grow the number of comprehensive sickle cell disease centers nationally, and the coordination gaps close as a side effect of physical concentration. “These centers are designed to bring together the expertise and services needed to support long-term disease management and preventive care,” he said.

Ivy and Kelly advanced a competency-and-network framing: the binding constraint is familiarity with the procedure and the maintenance of clinical skill at sites that see too few patients to sustain the practice; the remedy is awareness, training, and a network for case discussion. Ivy: “We need to make sure healthcare providers are aware of the National Alliance of Sickle Cell Center guidelines, and creating a network of providers than can discuss treatment strategies.” Kelly on the competency constraint: “Ideally this would be a therapy that could be offered at more sites, but if you don’t have a decent number of sickle cell patients in your area it’s very difficult to maintain the competencies of this therapy. It would be very hard for some rural centers to maintain a program like this.”

The two framings are not mutually exclusive, but they imply different priorities. The infrastructure framing concentrates resources at metropolitan nodes and accepts that rural patients travel. The competency-and-network framing attempts to push capability outward but confronts the volume requirement Kelly identified. A reconciliation would treat the comprehensive center as the diagnostic-and-training hub and the rural hospital as the maintenance-and-monitoring spoke, with referral paths running in both directions. The instruments that would carry this are familiar in other chronic-disease networks: shared referral protocols so the rural hematologist knows the candidacy criteria; telehealth consultation between the rural site and the apheresis team for complex cases; regional training rotations that keep rural clinicians current on the procedure; and a donor-matching network that lets the rural blood bank query the academic center’s inventory when local supply is short. The survey does not establish that any of these instruments are in place; it identifies the gap and leaves the architecture unspecified.

Patient hardship and the prospect-refuge inversion

Kelly described the hardship directly: “We see patients who do travel from some distance to receive their transfusions with us. It’s a hardship on them because already they have a chronic disease that can be debilitating and then they have to travel a long distance.” Read through Jay Appleton’s prospect-and-refuge vocabulary, the sickle cell patient at home is in refuge — a known environment with familiar providers and family support — but lacks prospect onto the procedure. The comprehensive center offers prospect onto the treatment but at the cost of leaving refuge. Read against Christopher Alexander’s pattern language — imported from outside health policy as an analogical lens — the broader environment appears to violate the “intimacy-gradient,” the principle that transition spaces should buffer users from the demands of distant institutions, by forcing patients to leave their home communities, their local providers, and their support networks to access a technology that already exists inside the same healthcare system. The relevant scale of the difficulty is regional and institutional: each treatment episode is a chronic subtraction from the patient’s reserves that compounds over decades of care.

The harder measurement

The 91-to-3 ratio, on this reading, is the visible expression of a system whose parts are largely present but whose geography, handoffs, and competency loops do not connect. The sequence that connects a patient to the technology crosses six documented decision points, each with a documented failure mode, anchored at a small number of geographically distant nodes that a Medicaid-enrolled, predominantly Black, Southern and rural patient population has difficulty reaching. Process distance, not medical scarcity, defines the gap.

Horst Rittel and Melvin Webber, who originated the term “wicked problem” in their work on social policy design, described problems whose definition shifts with the proposed solution and whose multiple stakeholders define the obstacle differently. The reported finding fits that description: providers, per the survey, name coordination between departments, limited donor supply, and lack of familiarity; patients name insurance coverage and a lack of awareness to ask about the therapy. The dominant-paradigm framing — that the obstacle is access to technology — is directly contradicted by the survey itself, in which 91 percent of providers reported having it. The cross-domain analogical framing places the situation within a familiar pattern of rural healthcare access and within the delivery problems that attend rare and inherited diseases.

Haubner’s survey measured the equipment; the harder measurement — how many patients actually arrive at the chair, how many donor units are coordinated, how many specialists maintain currency in the procedure, how many rural hospitals are tethered to a network that can guide them through a referral — is the work the survey begins to expose and the work its respondents, by their own account, have not yet completed. The question is whether the system that delivers the therapy can find the patient who needs it before the patient gives up trying.

Analytical techniques used in this piece

This analysis applies the methods below. Each links to a short, plain-English explainer you can read and reuse.

Genius Loci — Sense of Place: Reads the character and felt quality of a place.
Process Mapping: Lays out a process end to end — steps, hand-offs, and bottlenecks.
Wicked Problems: Treats a problem as wicked — no stopping rule, no clean test of success, every attempt consequential.